Publicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (16)

2022

  1. Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases

    Cancers, Vol. 14, Núm. 5

2021

  1. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

  2. Tumor mutational burden assessment in non-small-cell lung cancer samples: Results from the TMB 2 harmonization project comparing three NGS panels

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 5

2019

  1. Clinical challenges and implications of intratumor heterogeneity

    Revista Espanola de Patologia, Vol. 52, Núm. 4, pp. 234-241

2017

  1. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

    Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441

  2. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

    JAMA oncology, Vol. 3, Núm. 12, pp. e173290

  3. Treating KRAS -mutant NSCLC: Latest evidence and clinical consequences

    Therapeutic Advances in Medical Oncology, Vol. 9, Núm. 9, pp. 589-597

2016

  1. Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 113, Núm. 3, pp. E328-E337

2013

  1. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: Implications for outcomes and histologic classification

    Carcinogenesis, Vol. 34, Núm. 5, pp. 1031-1038

  2. DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas

    British Journal of Cancer, Vol. 108, Núm. 8, pp. 1732-1742

2012

  1. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection

    Journal of Pathology, Vol. 227, Núm. 1, pp. 42-52

2011

  1. Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico

    Revista Espanola de Patologia, Vol. 44, Núm. 1, pp. 32-48

2009

  1. Guidelines for HER2 testing in breast cancer. A national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 42, Núm. 1, pp. 3-16

  2. Guidelines for HER2 testing in breast cancer: A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 11, Núm. 6, pp. 363-375

2007

  1. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis

    Cancer Research, Vol. 67, Núm. 7, pp. 3450-3460

  2. Sox2: A possible driver of the basal-like phenotype in sporadic breast cancer

    Modern Pathology, Vol. 20, Núm. 4, pp. 474-481